Pneumonia Caused by Aspergillus spp (Invasive Aspergillosis)

How to Cite This Chapter: Loeb M, Kuś J, Jankowski M. Pneumonia Caused by Aspergillus spp (Invasive Aspergillosis). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Accessed November 27, 2020.
Last Updated: February 20, 2016
Last Reviewed: May 19, 2019
Chapter Information

Definition and EtiologyTop

Invasive aspergillosis is most commonly caused by Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, or Aspergillus terreus. Risk factors include neutropenia, prior antibiotic treatment, and chronic pulmonary disease.

Clinical features include fever, pleuritic pain, and hemoptysis. Chest radiographs may reveal peripheral solitary or multiple nodules, some of them with features of necrosis. CT scans reveal focal interstitial opacities surrounded by a cloud of a lower density image (halo sign).


The diagnosis of pneumonia is confirmed only if microscopic examination reveals the presence of fungi in lung biopsy specimens (in immunosuppressed patients also in bronchoalveolar lavage) and Aspergillus spp have been isolated in culture of the same specimen. An assay detecting Aspergillus spp antigen (galactomannan) in blood or bronchoalveolar lavage is useful in diagnostics. Using an optical density index (ODI) of 0.5 as a cutoff value, the sensitivity and specificity of the test to detect invasive aspergillosis is estimated to be ~80%. At a cutoff value of ODI 1.0, sensitivity is reduced to ~70% and specificity increased to ~90%. A positive sputum culture result is of low diagnostic value.


Use IV voriconazole (6 mg/kg every 12 hours for 2 doses on day 1, followed by 4 mg/kg bid; after achieving clinical improvement, you may switch to oral administration [4 mg/kg bid] starting on day 7). Alternatively, you may use IV amphotericin B as a liposomal formulation 3 to 5 mg/kg/d, as a lipid complex 5 mg/kg/d, or as a colloidal dispersion 3 to 4 mg/kg/d; use of amphotericin deoxycholate 0.7 to 1 mg/kg/d (maximum, 1.5 mg/kg/d) is associated with a higher risk of nephrotoxicity and other adverse effects.

In patients with less severe disease and patients who have achieved clinical improvement, consider itraconazole (200 mg tid for 3 days followed by 200 mg bid for tablets; note that dose depends on the formulation and that absorption can be variable) or oral voriconazole 200 mg bid for 2 to 5 months. In patients with a single lesion (particularly those with hemoptysis) and patients with lesions adjacent to major blood vessels, the pericardium, penetrating into the pleural cavity, or infiltrating the ribs, surgical resection of the lesion may be indicated during antifungal treatment. In patients with resistance to or intolerance of amphotericin or azole antifungal agents, use caspofungin (70 mg/d IV; in patients with a body weight ≤80 kg administer 50 mg/d from day 2 of treatment), micafungin (100-150 mg/d IV), or posaconazole (start from 200 mg orally qid, after clinical stabilization of the patient change to 400 mg orally bid).

The antifungal therapy should be continued until all signs and symptoms of the infection have been resolved and will often be prolonged in patients with persistent immunologic impairment. Although the duration has not been well established, treatment is generally continued for a minimum of 6 to 12 weeks. Primary combination therapy is not routinely recommended based on the lack of clinical data but may be considered for individual patients.

We would love to hear from you

  • Do you have any comments?
  • Have you found a mistake?
  • Would you like to suggest a feature?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.